motolimod   Click here for help

GtoPdb Ligand ID: 9026

Synonyms: VTX-2337
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Motolimod is an investigational Toll-like receptor 8 (TLR8) agonist [3].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 9
Topological polar surface area 79
Molecular weight 458.27
XLogP 4
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CCCN(C(=O)C1=Cc2ccc(cc2N=C(C1)N)c1ccc(cc1)C(=O)N1CCCC1)CCC
Isomeric SMILES CCCN(C(=O)C1=Cc2ccc(cc2N=C(C1)N)c1ccc(cc1)C(=O)N1CCCC1)CCC
InChI InChI=1S/C28H34N4O2/c1-3-13-31(14-4-2)28(34)24-17-23-12-11-22(18-25(23)30-26(29)19-24)20-7-9-21(10-8-20)27(33)32-15-5-6-16-32/h7-12,17-18H,3-6,13-16,19H2,1-2H3,(H2,29,30)
1. Chow LQM, Morishima C, Eaton KD, Baik CS, Goulart BH, Anderson LN, Manjarrez KL, Dietsch GN, Bryan JK, Hershberg RM et al.. (2017)
Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN.
Clin Cancer Res, 23 (10): 2442-2450. [PMID:27810904]
2. Dietsch GN. (2016)
Motolimod effectively drives immune activation in advanced cancer patients.
Oncoimmunology, 5 (5): e1126037. [PMID:27467937]
3. Lu H, Dietsch GN, Matthews MA, Yang Y, Ghanekar S, Inokuma M, Suni M, Maino VC, Henderson KE, Howbert JJ et al.. (2012)
VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC.
Clin Cancer Res, 18 (2): 499-509. [PMID:22128302]